ZURICH, March 30, 2017 /PRNewswire/ --
Takeda Pharmaceutical Company Limited ("Takeda") announced today that Giles Platford will assume the role of President of the Europe and Canada (EUCAN) Business Unit of Takeda. In this role he will lead business operations in the region effective April 1, 2017.
Giles Platford, who joined Takeda in 2009, is also a Corporate Officer and member of Takeda's Executive Team, reporting to Christophe Weber, President and Chief Executive Officer of Takeda.
"EUCAN has been a high performing region in the last few years, and I am fully confident that Giles, with his solid business ability and understanding of Takeda values, is the ideal choice to lead this business unit" said Christophe Weber. "His proven track record with the company in senior leadership roles across diverse geographies and cultures will no doubt bring a unique perspective and value to all facets of Takeda business in Europe and Canada."
A seasoned industry leader with more than 15 years of pharmaceutical experience, Giles Platford was formerly President of Emerging Markets for Takeda, which comprises Russia-CIS, Latin America, Middle East-Africa, China and Asia Pacific (excluding Japan). He oversaw the launch of Takeda's innovative pipeline across the region, and led the design and roll-out of Takeda's Global Access to Medicines (AtM) Programme.
Platford's other leadership roles at Takeda included Head of the Middle East, Turkey and Africa (META) region where he strengthened controls and re-engineered the business for growth. Prior to that he was General Manager in Brazil, where he led the transformation of Takeda into a top 10 pharmaceutical player, being externally recognised for the first time as one of the country's top employers and best companies to work for.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit https://www.takeda.com.
This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro forma," "potential," "target," "forecast," "guidance," "outlook" or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.
The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.
Takeda Pharmaceutical Company Limited
CONTACT: Contacts: Rob Gallo, +41-44-555-1339, Rob.Gallo@takeda.com, SadafHussain, +41-44-555-1488, Sadaf.Hussain@takeda.com